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The proband is a 6-year-old boy referred to the Clinical
Genetics Service with learning difficulties, autistic spec-
trum disorder and intellectual disability with no sig-
nificant family history. He was the third child of healthy,
nonconsanguineous, White European parents. There are
two healthy siblings who are fit and well. He was born
following a normal pregnancy at term with a birth weight
of 3.486 kg (50th centile) and there were no concerns
immediately after birth. He was noted to be delayed with
his development; he sat up at 14 months of age, walked at
20 months of age and was delayed with his speech. He
currently attends a mainstream school, but receives full-
time support and has been diagnosed with myopia and
astigmatism. On examination, he was noted to have
bilateral low-set ears, a bulbous tip to the nose and deep-
set eyes with accessory nipples (Fig. 1). His growth
parameters on presentation at 6 years of age were as
follows: height 123.5 cm (91st centile) and weight 25 kg
(91st centile), with a head circumference of 52 cm (25th
centile).
Investigations
Array comparative genomic hybridization (aCGH) was
performed as part of ongoing investigations to elucidate
the cause for the proband’s learning difficulties. aCGH
was performed on genomic DNA extracted from per-
ipheral blood lymphocytes from the proband and mother.
Fig. 1
(a, b) The proband, aged 6 years, showingAQ1 facial dysmorphism with bilateral low-set ears, a bulbous tip to the nose and deep-set eyes.
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DNA was applied to an BlueGnome 60-mer oligoarray,
printed in the 8× 60K International Standard
Cytogenomic Array Consortium configuration, according
to the manufacturer’s instructions, with pooled DNA
being used as a reference (Promega Corporation,
Madison, Wisconsin, USA). Slides were scanned using a
Genepix Personal 4100A scannerAQ2 (Axon Instruments) and
analysed using BlueGnome BlueFuse-Multi (version 3.0)
analysis software (BlueGnome, an Illumina Company,
Cambridge, UK).
Results from 60K aCGH showed a 90 kbp deletion of
Xq23 involving basepairs 110 373 400–110 464 093 (gen-
ome assembly GRCh37). Analysis of the deletion found
that the region encompassed part of the PAK3 gene (at
least exons 4–15 NM_001128166.1) (Fig. 2). The
mother’s arrayCGH showed normal chromosome analysis
with no evidence of deletion at Xq23, confirming the
deletion to be de novo in origin. This patient had been
investigated previously for Fragile-X syndrome
(negative).
Discussion
Small deletions of the X chromosome provide us with
novel insights into the genetic basis of X-linked intel-
lectual disability and correlation between the clinical
phenotype and genotype. We report a child with a novel
de-novo Xq23 deletion involving the PAK3 gene, refer-
red for clinical dysmorphism and developmental delay.
The PAK3 protein functions in regulating the actin
cytoskeleton of cells and is also involved in neuronal
stimulation and outgrowth in the foetal and adult brain
(Ma et al., 2012). Nonsense, missense and splice site
mutations within the PAK3 gene have all been previously
associated with nonsyndromic X-linked mental retarda-
tion (Donnelly et al., 1996; des Portes et al., 1997; Allen
















































ArrayCGH trace indicating the de-novo Xq23 deletion in the proband.
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Pieppo et al., 2007; Rejeb et al., 2008; Magini et al., 2014).
Analysis of these mutations suggested that they lead to
the inactivation of PAK3 protein functionality, either
through loss of catalytic enzyme activity or through
nonsense mutations resulting in premature termination of
protein product.
To date, this is the first case in which a large deletion
within PAK3 has led to an intellectual disability pheno-
type. Interestingly, where the clinical phenotypes of the
single nucleotide mutation families were available,
comparison between them and the phenotype discussed
shows a number of similarities, with facial dysmorphism,
speech delay and learning/behavioural abnormalities all
being present (Table 1). The phenotype of the patient
reported here with the PAK3 deletion is very similar to
that of patients reported with mutations in PAK3 with
normal stature, a relatively small head or microcephaly,
poor/absent speech and mild–moderate developmental
delay, suggesting a possible role of haploinsufficiency
causing the phenotype associated with mutations in
PAK3.
Analysis of haploinsufficiency information for PAK3
yields a haploinsufficiency score of 5.06% (Huang et al.,
2010). This finding suggests that inheritance of one
normal PAK3 allele is insufficient to maintain normal
protein function within the cell. Inheritance of a single
normal allele can be through deletion of PAK3 or func-
tional inactivation of the protein because of single
nucleotide mutations as reported previously.
Given the findings here, we suggest that the develop-
mental delay in this patient is a direct result of the
deletion within PAK3 and believe that this is the first case
to report an Xq23 deletion encompassing part of PAK3
associated with mental retardation. This finding provides
further evidence for the Xq23 loci as X-linked mental
retardation loci and that PAK3may play an important role
in normal development.
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of part of PAK3
Study participants 4 6 13 5 1 1 1
Mental retardation Mild Moderate (5)
Severe (1)
Borderline-mild Mild (2) Mild – Mild
Stature Normal Normal Normal Normal Normal Normal Normal
Head size Small – – Small (4) Small Small Relatively small




































No speech Poor inarticulate speech
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QUERIES AND / OR REMARKS
QUERY NO. Details Required Author's Response
Q1 Please provide the permission for Fig. [1] as the identity of the
patient is revealed.
Q2 Please give address information for ‘Axon Instruments’: town, state (if
applicable), and country.
